pharmaphorum
JANUARY 29, 2021
Sangamo CEO Sandy Macrae told us how his company is being cautious about the hype and finding ways to be financially viable in an emerging space. Maybe in 50 years’ time we’ll be using gene editing to lower cholesterol, but it won’t replace statins in anyone but those with life threatening mutations for a long time”.
Drug Discovery World
MAY 6, 2024
As companies move through the phases of development, they benefit from a long-established ecosystem of competency in clinical regulation. So, in this way there is a cross fertilisation from the bigger companies to newer ones. More than 400 companies now make up Lithuania’s life sciences sector 4.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
DECEMBER 14, 2022
Last month we saw some movement in the pharma world, but also in some of the orbiting worlds of agencies, consultancies, and pharma investors. The board helps Sixth Street’s healthcare and life sciences team to identify opportunities around CRISPR and gene editing. Read on for the hires headlines. New CEO joins UBC.
pharmaphorum
NOVEMBER 23, 2021
The DISC is the biggest investment AZ has ever made, and has been hailed by the pharma company’s chief executive Pascal Soriot as the centrepiece of what he believes could one day become a biotech hub to rival Boston and San Francisco in the US.
pharmaphorum
SEPTEMBER 29, 2020
There are a growing number of biotech and pharma companies that have established or are establishing such end-to-end cell therapy capabilities, which can also play into how collaborations are structured in the field. Case Study: From Technology Agreement to co-development and co-commercialisation partnership.
The Pharma Data
OCTOBER 20, 2020
MD Anderson has historically collaborated with biotechs and pharma companies to conduct cancer therapy research. Targeted therapies, genetic sequencing, gene editing, immunotherapies. Ochsner Health and LSU Health Shreveport have offered themselves as additional trial sites to increase patient access to studies. .
Drug Discovery World
NOVEMBER 16, 2022
On the point of consistency, the fact that organoids are a relatively new technology means that there isn’t a set ‘baseline’ in how companies grow them, with the differentiation potentially affecting research undertaken with them. “One One of the biggest pain points is really the consistency of organoids.
Expert insights. Personalized for you.
145 
Let's personalize your content